Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials.
Morabito A, Piccirillo MC, Maione P, Luciani A, Cavanna L, Bonanno L, Filipazzi V, Leo S, Cinieri S, Morgillo F, Burgio MA, Ferrara D, Rosetti F, Bianco R, Artioli F, Cortinovis D, Gebbia V, Fregoni V, Mencoboni M, Sandomenico C, Rossi A, Montanino A, Manzo A, Rocco G, Arenare L, Daniele G, Signoriello S, Gallo C, Perrone F, Gridelli C. Morabito A, et al. Among authors: manzo a. Lung Cancer. 2019 Jul;133:62-68. doi: 10.1016/j.lungcan.2019.05.009. Epub 2019 May 9. Lung Cancer. 2019. PMID: 31200830 Clinical Trial.
Metformin in lung cancer: rationale for a combination therapy.
Morgillo F, Sasso FC, Della Corte CM, Festino L, Manzo A, Martinelli E, Troiani T, Capuano A, Ciardiello F. Morgillo F, et al. Among authors: manzo a. Expert Opin Investig Drugs. 2013 Nov;22(11):1401-9. doi: 10.1517/13543784.2013.828691. Epub 2013 Aug 12. Expert Opin Investig Drugs. 2013. PMID: 23937224 Review.
Focus on Nintedanib in NSCLC and Other Tumors.
Manzo A, Carillio G, Montanino A, Costanzo R, Sandomenico C, Rocco G, Morabito A. Manzo A, et al. Front Med (Lausanne). 2016 Dec 19;3:68. doi: 10.3389/fmed.2016.00068. eCollection 2016. Front Med (Lausanne). 2016. PMID: 28066768 Free PMC article. Review.
Angiogenesis Inhibitors in NSCLC.
Manzo A, Montanino A, Carillio G, Costanzo R, Sandomenico C, Normanno N, Piccirillo MC, Daniele G, Perrone F, Rocco G, Morabito A. Manzo A, et al. Int J Mol Sci. 2017 Sep 21;18(10):2021. doi: 10.3390/ijms18102021. Int J Mol Sci. 2017. PMID: 28934120 Free PMC article. Review.
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.
Capelletto E, Migliorino MR, Morabito A, Chiari R, Grossi F, Tiseo M, Costanzo FD, Delmonte A, Romano G, Galetta D, Scotti V, Gregorc V, Pisconti S, Ceresoli GL, Del Conte A, Ciuffreda L, Colantonio I, Bria E, Ricciardi S, Manzo A, Metro G, Morelli AM, Critelli R, Pacchiana MV, Stura I, Migliaretti G, Novello S. Capelletto E, et al. Among authors: manzo a. Lung Cancer. 2019 Aug;134:210-217. doi: 10.1016/j.lungcan.2019.06.028. Epub 2019 Jun 27. Lung Cancer. 2019. PMID: 31319983 Clinical Trial.
Pembrolizumab in lung cancer: current evidence and future perspectives.
Palumbo G, Carillio G, Manzo A, Montanino A, Sforza V, Costanzo R, Sandomenico C, Manna C, Luca G, Piccirillo MC, Daniele G, Cecio R, Botti G, Totaro G, Muto P, Picone C, Esposito G, Normanno N, Morabito A. Palumbo G, et al. Among authors: manzo a. Future Oncol. 2019 Oct;15(29):3327-3336. doi: 10.2217/fon-2019-0073. Epub 2019 Aug 21. Future Oncol. 2019. PMID: 31432705 Clinical Trial.
The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer.
Manzo A, Carillio G, Montanino A, Sforza V, Palumbo G, Esposito G, Costanzo R, Sandomenico C, La Manna C, Martucci N, La Rocca A, De Luca G, Piccirillo MC, De Cecio R, Botti G, Totaro G, Muto P, Picone C, Normanno N, Morabito A. Manzo A, et al. Expert Opin Drug Saf. 2020 Jul;19(7):775-783. doi: 10.1080/14740338.2020.1767584. Epub 2020 May 26. Expert Opin Drug Saf. 2020. PMID: 32400223 Review.
152 results